A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Vilazodone (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 06 Oct 2016 Status changed from active, no longer recruiting to completed.
- 15 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2015 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.